Amber J Giles
Overview
Explore the profile of Amber J Giles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1075
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ratnam N, Sonnemann H, Frederico S, Chen H, Hutchinson M, Dowdy T, et al.
Front Oncol
. 2021 Aug;
11:719091.
PMID: 34336705
Glioblastoma (GBM) is an aggressive brain malignancy with a dismal prognosis. With emerging evidence to disprove brain-immune privilege, there has been much interest in examining immunotherapy strategies to treat central...
2.
Ravin R, Cai T, Pursley R, Garmendia-Cedillos M, Pohida T, Freidlin R, et al.
Biophys J
. 2020 Nov;
119(12):2378-2390.
PMID: 33189686
We have developed a novel, to our knowledge, in vitro instrument that can deliver intermediate-frequency (100-400 kHz), moderate-intensity (up to and exceeding 6.5 V/cm pk-pk) electric fields (EFs) to cell...
3.
Giles A, Hao S, Padget M, Song H, Zhang W, Lynes J, et al.
JCI Insight
. 2019 Sep;
4(20).
PMID: 31536478
Meningiomas are the most common adult primary tumor of the central nervous system, but there are no known effective medical therapies for recurrent meningioma, particularly for World Health Organization grade...
4.
Jung J, Zhang Y, Celiku O, Zhang W, Song H, Williams B, et al.
Cancer Res
. 2019 Sep;
79(20):5218-5232.
PMID: 31488423
Cancer cells rely on mitochondrial functions to regulate key survival and death signals. How cancer cells regulate mitochondrial autophagy (mitophagy) in the tumor microenvironment as well as utilize mitophagy as...
5.
Nettey L, Giles A, Chattopadhyay P
Cytometry A
. 2018 Oct;
93(11):1094-1096.
PMID: 30347136
No abstract available.
6.
Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, et al.
Neurosurgery
. 2018 Sep;
84(4):945-953.
PMID: 30189044
Background: Glioblastoma is the most common primary malignancy of the brain, with a dismal prognosis. Immunomodulation via checkpoint inhibition has provided encouraging results in non-CNS malignancies, but prediction of responders...
7.
Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, et al.
Neurosurgery
. 2018 Jul;
85(2):280-289.
PMID: 30011045
Background: Checkpoint inhibition has demonstrated clinical efficacy in a variety of solid tumors. Reports of programmed death ligand 1 (PD-L1) expression in glioblastoma are highly variable (ranging from 6% to...
8.
Giles A, Hutchinson M, Sonnemann H, Jung J, Fecci P, Ratnam N, et al.
J Immunother Cancer
. 2018 Jun;
6(1):51.
PMID: 29891009
Background: Corticosteroids are routinely utilized to alleviate edema in patients with intracranial lesions and are first-line agents to combat immune-related adverse events (irAEs) that arise with immune checkpoint blockade treatment....
9.
Ratnam N, Gilbert M, Giles A
Neuro Oncol
. 2018 May;
21(1):37-46.
PMID: 29771386
Glioblastoma (GBM) is a highly malignant CNS tumor with very poor survival despite intervention with conventional therapeutic strategies. Although the CNS is separated from the immune system by the blood-brain...
10.
Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles A, et al.
Neuro Oncol
. 2018 Jan;
20(6):799-809.
PMID: 29294092
Background: Standard therapy for chordoma consists of surgical resection followed by high-dose irradiation. Protein phosphatase 2A (PP2A) is a ubiquitously expressed serine/threonine phosphatase involved in signal transduction, cell cycle progression,...